Advertisement

Potentially Malignant Disorders of the Oral Cavity

  • David C. Williams
  • William T. McGaw
Part of the Head and Neck Cancer Clinics book series (HNCC)

Abstract

The term ‘potentially malignant disorder’ (PMD) of the oral cavity was created by a working group of the WHO Collaborating Centre for Oral Pathology and Precancer. It is currently used to describe ‘white plaques of questionable risk, having excluded other known diseases and diseases that carry no increased risk for cancer’ [1]. Not all lesions under the umbrella of PMD transform into cancer, but they are still included as they belong to a morphological group that has an increased potential for malignant transformation [1, 2]. Several clinical entities can be classified as a PMD, with the most common being leukoplakia, erythroplakia, lichen planus, oral submucous fibrosis, palatal lesions in reverse smokers, actinic keratosis and hereditary disorders with increased risk [1]. This chapter will examine oral leukoplakia, oral lichen planus (OLP), erythroplakia and oral submucous fibrosis; the clinical presentation, prevalence and risk factors, histology, molecular genetics, risk of malignant transformation and treatment will be discussed.

Keywords

Malignant Transformation Buccal Mucosa Actinic Keratosis Lichen Planus Oral Submucous Fibrosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007;36:575–80.PubMedCrossRefGoogle Scholar
  2. 2.
    van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa: Terminology, classification and present concepts of management. Oral Oncol 2009;45:317–23.PubMedCrossRefGoogle Scholar
  3. 3.
    van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa: Present concepts of management. Oral Oncol 2010;46:423–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Ribeiro AS, Salles PR, da Silva TA, et al. A review of the non-surgical treatment of oral leukoplakia. Int J Dent 2010;2010:186018.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Roed-Petersen B. Effect on oral leukoplakia of reducing or ceasing tobacco smoking. Acta Derm Venereol 1982;62:164–7.PubMedGoogle Scholar
  6. 6.
    Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: An overview of the literature. J Oral Pathol Med 2008;37:1–10.PubMedCrossRefGoogle Scholar
  7. 7.
    Hashibe M, Jacob BJ, Thomas G, et al. Socioeconomic status, lifestyle factors and oral premalignant lesions. Oral Oncol 2003;39:664–71.PubMedCrossRefGoogle Scholar
  8. 8.
    Dietrich T, Reichart PA, Scheifele C. Clinical risk factors of oral leukoplakia in a representative sample of the US population. Oral Oncol 2004;40:158–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Bagan JV, Jimenez Y, Murillo J, et al. Lack of association between proliferative verrucous leukoplakia and human papillomavirus infection. J Oral Maxillofac Surg 2007;65:46–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Eugene N. SJ (ed). Cancer of the head and neck. 3rd ed. Philadelphia: WWB, Saunders; 1996.Google Scholar
  11. 11.
    Kujan O, Khattab A, Oliver RJ, et al. Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: An attempt to understand the sources of variation. Oral Oncol 2007;43:224–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Holmstrup P, Vedtofte P, Reibel J, et al. Long-term treatment outcome of oral premalignant lesions. Oral Oncol 2006;42:461–74.PubMedCrossRefGoogle Scholar
  13. 13.
    Gupta PC, Mehta FS, Daftary DK, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol 1980;8:283–333.PubMedCrossRefGoogle Scholar
  14. 14.
    Lind PO. Malignant transformation in oral leukoplakia. Scand J Dent Res 1987;95:449–55.PubMedGoogle Scholar
  15. 15.
    Petti S. Pooled estimate of world leukoplakia prevalence: A systematic review. Oral Oncol 2003;39:770–80.PubMedCrossRefGoogle Scholar
  16. 16.
    Bilodeau E, Alawi F, Costello BJ, et al. Molecular diagnostics for head and neck pathology. Oral Maxillofac Surg Clin North Am 2010;22:183–94.PubMedCrossRefGoogle Scholar
  17. 17.
    Mithani SK, Mydlarz WK, Grumbine FL, et al. Molecular genetics of premalignant oral lesions. Oral Dis 2007;13:126–33.PubMedCrossRefGoogle Scholar
  18. 18.
    Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000;6:357–62.PubMedGoogle Scholar
  19. 19.
    Partridge M, Emilion G, Pateromichelakis S, et al. Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncol 1998;34:77–83.PubMedCrossRefGoogle Scholar
  20. 20.
    Lee JS, Kim SY, Hong WK, et al. Detection of chromosomal polysomy in oral leukoplakia, a premalignant lesion. J Natl Cancer Inst 1993;85:1951–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Fujimoto R, Kamata N, Yokoyama K, et al. Expression of telomerase components in oral keratinocytes and squamous cell carcinomas. Oral Oncol 2001;37:132–40.PubMedCrossRefGoogle Scholar
  22. 22.
    Kovesi G, Szende B. Changes in apoptosis and mitotic index, p53 and Ki67 expression in various types of oral leukoplakia. Oncology 2003;65:331–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Thomson PJ, Hamadah O. Cancerisation within the oral cavity: The use of ‘field mapping biopsies’ in clinical management. Oral Oncol 2007;43:20–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Schepman KP, Bezemer PD, van der Meij EH, et al. Tobacco usage in relation to the anatomical site of oral leukoplakia. Oral Dis 2001;7:25–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Lodi G, Porter S. Management of potentially malignant disorders: Evidence and critique. J Oral Pathol Med 2008;37:63–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Sako K, Marchetta FC, Hayes RL. Cryotherapy of intraoral leukoplakia. Am J Surg 1972;124:482–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Meltzer C. Surgical management of oral and mucosal dysplasias: The case for laser excision. J Oral Maxillofac Surg 2007;65:293–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Lodi G, Sardella A, Bez C, et al. Interventions for treating oral leukoplakia. Cochrane Database Syst Rev 2006;4:CD001829.PubMedGoogle Scholar
  29. 29.
    Stich HF, Hornby AP, Mathew B, et al. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988;40:93–101.PubMedCrossRefGoogle Scholar
  30. 30.
    Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: An assessment. Oral Oncol 1997;33:231–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Piattelli A, Fioroni M, Santinelli A, et al. Bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: A pilot study. Oral Oncol 1999;35:314–20.PubMedCrossRefGoogle Scholar
  32. 32.
    Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Gaeta GM, Gombos F, Femiano F, et al. Acitretin and treatment of the oral leucoplakias. A model to have an active molecules release. J Eur Acad Dermatol Venereol 2000;14:473–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Fan KF, Hopper C, Speight PM, et al. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer 1996;78:1374–83.PubMedCrossRefGoogle Scholar
  35. 35.
    Chen HM, Yu CH, Tu PC, et al. Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy. Lasers Surg Med 2005;37:114–22.PubMedCrossRefGoogle Scholar
  36. 36.
    Sieron A, Adamek M, Kawczyk-Krupka A, et al. Photodynamic therapy (PDT) using topically applied delta-aminolevulinic acid (ALA) for the treatment of oral leukoplakia. J Oral Pathol Med 2003;32:330–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Kubler A, Haase T, Rheinwald M, et al. Treatment of oral leukoplakia by topical application of 5-aminolevulinic acid. Int J Oral Maxillofac Surg 1998;27:466–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Bouquot JE. Common oral lesions found during a mass screening examination. J Am Dent Assoc 1986;112:50–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Scully C, Beyli M, Ferreiro MC, et al. Update on oral lichen planus: Etiopathogenesis and management. Crit Rev Oral Biol Med 1998;9:86–122.PubMedCrossRefGoogle Scholar
  40. 40.
    Markopoulos A, Kayavis I, Paleologoy A, et al. Oral lichen planus. A clinical study of 228 cases. Hell Stomatol Chron 1989;33:107–11.PubMedGoogle Scholar
  41. 41.
    Lodi G, Scully C, Carrozzo M, et al. Current controversies in oral lichen planus: Report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:40–51.PubMedCrossRefGoogle Scholar
  42. 42.
    Scully C, Carrozzo M. Oral mucosal disease: Lichen planus. Br J Oral Maxillofac Surg 2008;46:15–21.PubMedCrossRefGoogle Scholar
  43. 43.
    Epstein JB, Wan LS, Gorsky M, et al. Oral lichen planus: Progress in understanding its malignant potential and the implications for clinical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96:32–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study of 570 patients with oral lichen planus: Persistence, remission, and malignant association. Oral Surg Oral Med Oral Pathol 1985;60:30–4.PubMedCrossRefGoogle Scholar
  45. 45.
    Gorsky M, Raviv M, Moskona D, et al. Clinical characteristics and treatment of patients with oral lichen planus in Israel. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:644–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Kilpi AM. Activation marker analysis of mononuclear cell infiltrates of oral lichen planus in situ. Scand J Dent Res 1987;95:174–80.PubMedGoogle Scholar
  47. 47.
    Jungell P, Konttinen YT, Nortamo P, et al. Immunoelectron microscopic study of distribution of T-cell subsets in oral lichen planus. Scand J Dent Res 1989;97:361–7.PubMedGoogle Scholar
  48. 48.
    Santoro A, Majorana A, Bardellini E, et al. NF-kappaB expression in oral and cutaneous lichen planus. J Pathol 2003;201:466–72.PubMedCrossRefGoogle Scholar
  49. 49.
    Karatsaidis A, Schreurs O, Axell T, et al. Inhibition of the transforming growth factor-beta/Smad signaling pathway in the epithelium of oral lichen. J Invest Dermatol 2003;121:1283–90.PubMedCrossRefGoogle Scholar
  50. 50.
    Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: Facts and controversies. Clin Dermatol 2010;28:100–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Lodi G, Scully C, Carrozzo M, et al. Current controversies in oral lichen planus: Report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:164–78.PubMedCrossRefGoogle Scholar
  52. 52.
    Potts AJ, Hamburger J, Scully C. The medication of patients with oral lichen planus and the association of nonsteroidal anti-inflammatory drugs with erosive lesions. Oral Surg Oral Med Oral Pathol 1987;64:541–3.PubMedCrossRefGoogle Scholar
  53. 53.
    Firth NA, Reade PC. Angiotensin-converting enzyme inhibitors implicated in oral mucosal lichenoid reactions. Oral Surg Oral Med Oral Pathol 1989;67:41–4.PubMedCrossRefGoogle Scholar
  54. 54.
    Robertson WD, Wray D. Ingestion of medication among patients with oral keratoses including lichen planus. Oral Surg Oral Med Oral Pathol 1992;74:183–5.PubMedCrossRefGoogle Scholar
  55. 55.
    Smart ER, Macleod RI, Lawrence CM. Resolution of lichen planus following removal of amalgam restorations in patients with proven allergy to mercury salts: A pilot study. Br Dent J 1995;178:108–12.PubMedCrossRefGoogle Scholar
  56. 56.
    Laeijendecker R, van Joost T. Oral manifestations of gold allergy. J Am Acad Dermatol 1994;30:205–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Rojo-Moreno JL, Bagan JV, Rojo-Moreno J, et al. Psychologic factors and oral lichen planus. A psychometric evaluation of 100 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:687–91.PubMedCrossRefGoogle Scholar
  58. 58.
    McCartan BE. Psychological factors associated with oral lichen planus. J Oral Pathol Med 1995;24:273–5.PubMedCrossRefGoogle Scholar
  59. 59.
    Rebora A. Lichen planus and the liver. Lancet 1981;2:805–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Lodi G, Giuliani M, Majorana A, et al. Lichen planus and hepatitis C virus: A multicentre study of patients with oral lesions and a systematic review. Br J Dermatol 2004;151:1172–81.PubMedCrossRefGoogle Scholar
  61. 61.
    Grote M, Reichart PA, Berg T, et al. Hepatitis C virus (HCV) infection and oral lichen planus. J Hepatol 1998;29:1034–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Henderson L, Muir M, Mills PR, et al. Oral health of patients with hepatitis C virus infection: A pilot study. Oral Dis 2001;7:271–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Lodi G, Olsen I, Piattelli A, et al. Antibodies to epithelial components in oral lichen planus (OLP) associated with hepatitis C virus (HCV) infection. J Oral Pathol Med 1997;26:36–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Arrieta JJ, Rodriguez-Inigo E, Casqueiro M, et al. Detection of hepatitis C virus replication by in situ hybridization in epithelial cells of anti-hepatitis C virus-positive patients with and without oral lichen planus. Hepatology 2000;32:97–103.Google Scholar
  65. 65.
    Bigby M. The relationship between lichen planus and hepatitis C clarified. Arch Dermatol 2009;145:1048–50.PubMedCrossRefGoogle Scholar
  66. 66.
    Plemons JM, Rees TD, Zachariah NY. Absorption of a topical steroid and evaluation of adrenal suppression in patients with erosive lichen planus. Oral Surg Oral Med Oral Pathol 1990;69:688–93.PubMedCrossRefGoogle Scholar
  67. 67.
    Hatchuel DA, Peters E, Lemmer J, et al. Candidal infection in oral lichen planus. Oral Surg Oral Med Oral Pathol 1990;70:172–5.PubMedCrossRefGoogle Scholar
  68. 68.
    Carbone M, Conrotto D, Carrozzo M, et al. Topical corticosteroids in association with miconazole and chlorhexidine in the long-term management of atrophic-erosive oral lichen planus: A placebo-controlled and comparative study between clobetasol and fluocinonide. Oral Dis 1999;5:44–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Zegarelli DJ. Treatment of oral lichen planus with topical vitamin A acid. J Oral Med 1984;39:186–91.PubMedGoogle Scholar
  70. 70.
    Al Johani KA, Hegarty AM, Porter SR, et al. Calcineurin inhibitors in oral medicine. J Am Acad Dermatol 2009;61:829–40.PubMedCrossRefGoogle Scholar
  71. 71.
    Conrotto D, Carbone M, Carrozzo M, et al. Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: A double-blind, randomized controlled trial. Br J Dermatol 2006;154:139–45.PubMedCrossRefGoogle Scholar
  72. 72.
    Rozycki TW, Rogers RS 3rd, Pittelkow MR, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: A series of 13 patients. J Am Acad Dermatol 2002;46:27–34.PubMedCrossRefGoogle Scholar
  73. 73.
    Morrison L, Kratochvil FJ 3rd, Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol 2002;47:617–20.PubMedCrossRefGoogle Scholar
  74. 74.
    Becker JC, Houben R, Vetter CS, et al. The carcinogenic potential of tacrolimus ointment beyond immune suppression: A hypothesis creating case report. BMC Cancer 2006;6:7.PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003;149:960–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Woo TY. Systemic isotretinoin treatment of oral and cutaneous lichen planus. Cutis 1985;35:385–6, 390–1, 393.Google Scholar
  77. 77.
    Lear JT, English JS. Erosive and generalized lichen planus responsive to azathioprine. Clin Exp Dermatol 1996;21:56–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Hallopeau H. Sur un cas de lichen de Wilson gingival avec neoplasie voisine dans la region maxillaire. Bull Soc Fr Dermatol Syphiligr 1910;17:32.Google Scholar
  79. 79.
    Krutchkoff DJ, Cutler L, Laskowski S. Oral lichen planus: The evidence regarding potential malignant transformation. J Oral Pathol 1978;7:1–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Van der Meij EH, Schepman KP, van der Wal JE, et al. A review of the recent literature regarding malignant transformation of oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88:307–10.PubMedCrossRefGoogle Scholar
  81. 81.
    Gonzalez-Moles MA, Scully C, Gil-Montoya JA. Oral lichen planus: Controversies surrounding malignant transformation. Oral Dis 2008;14:229–43.PubMedCrossRefGoogle Scholar
  82. 82.
    Mattsson U, Jontell M, Holmstrup P. Oral lichen planus and malignant transformation: Is a recall of patients justified? Crit Rev Oral Biol Med 2002;13:390–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Gandolfo S, Richiardi L, Carrozzo M, et al. Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: A follow-up study in an Italian population. Oral Oncol 2004;40:77–83.PubMedCrossRefGoogle Scholar
  84. 84.
    Zhang L, Cheng X, Li Y, et al. High frequency of allelic loss in dysplastic lichenoid lesions. Lab Invest 2000;80:233–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Kim J, Yook JI, Lee EH, et al. Evaluation of premalignant potential in oral lichen planus using interphase cytogenetics. J Oral Pathol Med 2001;30:65–72.PubMedCrossRefGoogle Scholar
  86. 86.
    Krogh P, Holmstrup P, Thorn JJ, et al. Yeast species and biotypes associated with oral leukoplakia and lichen planus. Oral Surg Oral Med Oral Pathol 1987;63:48–54.PubMedCrossRefGoogle Scholar
  87. 87.
    Cox M, Maitland N, Scully C. Human herpes simplex-1 and papillomavirus type 16 homologous DNA sequences in normal, potentially malignant and malignant oral mucosa. Eur J Cancer B Oral Oncol 1993;29B:215–19.PubMedCrossRefGoogle Scholar
  88. 88.
    Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530–4.PubMedCrossRefGoogle Scholar
  89. 89.
    Barnard NA, Scully C, Eveson JW, et al. Oral cancer development in patients with oral lichen planus. J Oral Pathol Med 1993;22:421–4.PubMedCrossRefGoogle Scholar
  90. 90.
    Sudbo J, Ried T, Bryne M, et al. Abnormal DNA content predicts the occurrence of carcinomas in non-dysplastic oral white patches. Oral Oncol 2001;37:558–65.PubMedCrossRefGoogle Scholar
  91. 91.
    Zhang L, Michelsen C, Cheng X, et al. Molecular analysis of oral lichen planus. A premalignant lesion? Am J Pathol 1997;151:323–7.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Reichart PA, Philipsen HP. Oral erythroplakia—a review. Oral Oncol 2005;41:551–61.PubMedCrossRefGoogle Scholar
  93. 93.
    Kramer IR, Lucas RB, Pindborg JJ, et al. Definition of leukoplakia and related lesions: An aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 1978;46:518–39.PubMedCrossRefGoogle Scholar
  94. 94.
    Pindborg JJ, Reichart PA, Smith CJ, van der Waal I, in collaboaration with Sobin L.H. and pathologists in 9 countries editors. Histological typing of cancer and precancer of the oral mucosa. 2nd ed. Berlin, New York, Tokyo: Springer Verlag; 1997.Google Scholar
  95. 95.
    Shafer WG, Waldron CA. Erythroplakia of the oral cavity. Cancer 1975;36:1021–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Hashibe M, Mathew B, Kuruvilla B, et al. Chewing tobacco, alcohol, and the risk of erythroplakia. Cancer Epidemiol Biomarkers Prev 2000;9:639–45.PubMedGoogle Scholar
  97. 97.
    Thomas G, Hashibe M, Jacob BJ, et al. Risk factors for multiple oral premalignant lesions. Int J Cancer 2003;107:285–91.PubMedCrossRefGoogle Scholar
  98. 98.
    Jacob BJ, Straif K, Thomas G, et al. Betel quid without tobacco as a risk factor for oral precancers. Oral Oncol 2004;40:697–704.PubMedCrossRefGoogle Scholar
  99. 99.
    Sudbo J, Kildal W, Johannessen AC, et al. Gross genomic aberrations in precancers: Clinical implications of a long-term follow-up study in oral erythroplakias. J Clin Oncol 2002;20:456–62.PubMedCrossRefGoogle Scholar
  100. 100.
    Qin GZ, Park JY, Chen SY, et al. A high prevalence of p53 mutations in pre-malignant oral erythroplakia. Int J Cancer 1999;80:345–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Tilakaratne WM, Klinikowski MF, Saku T, et al. Oral submucous fibrosis: Review on aetiology and pathogenesis. Oral Oncol 2006;42:561–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Rajendran R, Vijayakumar T, Vasudevan DM. An alternative pathogenetic pathway for oral submucous fibrosis (OSMF). Med Hypotheses 1989;30:35–7.PubMedCrossRefGoogle Scholar
  103. 103.
    Aziz SR. Coming to America: Betel nut and oral submucous fibrosis. J Am Dent Assoc 2010;141:423–8.PubMedCrossRefGoogle Scholar
  104. 104.
    Maher R, Lee AJ, Warnakulasuriya KA, et al. Role of areca nut in the causation of oral submucous fibrosis: A case–control study in Pakistan. J Oral Pathol Med 1994;23:65–9.Google Scholar
  105. 105.
    Vilcek J, Palombella VJ, Henriksen-DeStefano D, et al. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 1986;163:632–43.PubMedCrossRefGoogle Scholar
  106. 106.
    Liu CJ, Lee YJ, Chang KW, et al. Polymorphism of the MICA gene and risk for oral submucous fibrosis. J Oral Pathol Med 2004;33:1–6.PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2012

Authors and Affiliations

  1. 1.Division of General Surgery2D4.39 Walter Mackenzie Health Sciences CenterEdmontonCanada
  2. 2.Division of Oral Medicine and PathologyUniversity of AlbertaEdmontonCanada

Personalised recommendations